Introgen Therapeutics

A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.

Phase 1, Recruiting, 2023, 106 people, 5 Jun 2026, clinicaltrials.gov

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Phase 2/3, Recruiting, 2026, 750 people, 26 Jan 2026, clinicaltrials.gov

NCT07245771

Collaborator, Phase 1/2, Recruiting, 2025, 104 people, 24 Nov 2025, clinicaltrials.gov

NCT05004753

Phase 4, Completed, 2020, 120 people, 13 Aug 2021, clinicaltrials.gov

NCT04809818

Phase 1, Completed, 2021, 65 people, 22 Mar 2021, clinicaltrials.gov

NCT03974932

Phase 3, Completed, 2019, 116 people, 5 Jun 2019, clinicaltrials.gov

NCT03716856

Collaborator, Phase 1, Status unknown, 2018, 11 people, 23 Oct 2018, clinicaltrials.gov

NCT02933775

Collaborator, Phase 1, Status unknown, 2016, 45 people, 14 Oct 2016, clinicaltrials.gov

NCT02862145

Phase 1/2, Withdrawn, 2016, 0 people, 10 Aug 2016, clinicaltrials.gov

NCT02106494

Phase 3, Completed, 2014, 942 people, 8 Apr 2014, clinicaltrials.gov

NCT01361308

Phase 3, Completed, 2011, 614 people, 26 May 2011, clinicaltrials.gov

NCT00343460

Phase 3, Completed, 2006, 1,428 people, 23 Jun 2006, clinicaltrials.gov

NCT00044993

Phase 2, Completed, 2002, 27 Jan 2003, clinicaltrials.gov